Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Tuberculosis (Edinb). 2022 Oct 4;137:102269. doi: 10.1016/j.tube.2022.102269

Fig. 4. Omadacycline and M. kansasii.

Fig. 4.

(A) Picture of MIC plates, showing trailing effects. Considering trailing effect, 100% growth inhibition was not achieved with the highest concentration of 128 mg/L concentration when no drug was supplemented to account for the drug degradation. However, 100% growth inhibition was recorded to 32mg/L with daily 50% drug supplementation. (B) The inhibitory sigmoidal maximal effect model showed better kill and lower EC50 with daily drug supplementation; data points for omadacycline 16mg/L and 32mg/L in wells with supplementation were automatically eliminated by program as outliers and are not shown. (Stasis, bacterial burden in the inoculum; LLOD, lower limit of detection by CFU/mL). C) With daily drug supplementation, the drug concentration to reduce the bacterial burden 2 log10 CFU/mL was 4-fold lower. Negative numbers on the y-axis indicate bacterial growth compared to stasis, whereas positive numbers mean kill below stasis